Nephrogenic systemic fibrosis: An emerging entity

International Urology and Nephrology

Volumn 40, Issue 3, 2008, Pages 715-724

  Saxena, Sandip K ^a   Sharma, Manjuri ^a   Patel, Mital ^a   Oreopoulos, Dimitrios ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gadolinium in kidney diseases; Gadolinium toxicities; Gadolinium related skin diseases; Nephrogenic fibrosing dermopathy; Nephrogenic systemic fibrosis; NFD; NSF

Indexed keywords

ALPHA INTERFERON; CALCIPOTRIOL; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IMMUNOGLOBULIN; IODINATED CONTRAST MEDIUM; METHOTREXATE; PENTOXIFYLLINE; PREDNISONE; PSORALEN;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CONNECTIVE TISSUE DISEASE; CONTRAST ENHANCEMENT; DIAPHRAGM DISEASE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG MEGADOSE; DRUG STRUCTURE; DRUG WITHDRAWAL; ESOPHAGUS DISEASE; HEART MUSCLE FIBROSIS; HUMAN; JOINT CONTRACTURE; LUNG FIBROSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MYOFIBROSIS; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PUVA; REVIEW; SKELETAL MUSCLE; SKIN BIOPSY; SKIN FIBROSIS; UNSPECIFIED SIDE EFFECT;

CONTRAST MEDIA; GADOLINIUM; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROGENIC FIBROSING DERMOPATHY; PROGNOSIS; RISK FACTORS;

EID: 48549097160     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-008-9361-8     Document Type: Review

References (65)

1. Cowper SE, Robin HS, Steinberg SM et al (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 (9234):1000-1001, also available at http://www.icnfdr.org
2. Cowper SE (2005) Nephrogenic systemic fibrosis: The nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46(4):763-765
3. Galan A, Cowper SE, Bucala R (2006) Nephrogenic systemic fibrosis (Nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18(6):614-617
4. Gibson SE, Ferver Cf, Prayson RA (2006) Multiorgan involvement in nephrogenic fibrosing dermopathy: An autopsy case and review of the literature. Arch Pathol Lab Med 130(2):209-212
5. Cowper SE (2003) Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol 15(6):785-790
6. McNeill AM, Barr RJ (2002) Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Dermatol Jun 41(6):364-367
7. Grobner T (2006) Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis. Nephrol Dial Transplant 21:1104-1108
8. Bellin MF (2006) MR contrast agents, the old and the new. Eur J Radiol 60:314-323
9. Lorusso V, Pascolo L, Fernetti C, Anelli PL, Uggeri F, Tiribelli C (2005) Magnetic resonance contrast agents: From the bench to the patient. Curr Pharm Design 11:4079-4098
10. Pintaske J, Martirosian P, Graf H et al (2006) Relaxivity of Magnevist and Gadovist and Multihence in human blood plasm at 0.2, 1.5, and 3 telsa. Invest radiol 41:213-221
11. Knopp MV, Balzer T, Esser M et al (2006) Assesment of utilization and pharmacovigilance based on spontaneous adverse event reporting on Gadopentetate dimeglumine as MR contrast agent after 45 milion administration and 15 year of clinical use. Invest radiol 41:491-499
12. Shellock FG, Parker JR, Venetianer C et al (2006) Safety of Gadobenate dimeglumine: Summery of finding from clinical studies and post marketing surveillance. Invest Radiol 41:500-509
13. Richard C. Semelka, medscape CME MD Professor, University of North Carolina, Chapel Hill; Vice Chair, Department of Radiology, UNC Hospitals, Chapel Hill, North Carolina
14. Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in Nephrogenic fibrosing dermopathy. J Am Acad Dermatol 1:27-30
15. www.fda.gov/cder/drug/infopage/gcca/
16. Ogawa M, LaRue AC, Drake CJ (2006) Hematopoietic origin of fibroblasts/ myofibroblasts: Its pathophysiologic implications. Blood 108:2893-2896
17. Socolovsky M (2007) Molecular insights into stress erythropoiesis. Curr Opin Hematol 14:215-224
18. Bahlmann FH, DeGroot K, Duckert T, Niemczyk E, Bahlmann E, Boehm SM, Haller H, Fliser D (2003) Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64:1648-1652
19. Neves PL, Morgado E (2006) Nutritional and inflammatory stauts influence darbapoetin dose in pre-dialysis elderly patients Int J Urol Nephrol 38(3):811-813
20. Fathke C, Wilson L, Hutter J, Kapoor V, Smith A, Hocking A, Isik F (2004) Contribution of bone marrow-derived cells to skin: Collagen deposition and wound repair. Stem Cells 22:812-822
21. Liu J, Finkel T (2006) Stem cell aging: What bleach can teach. Nat Med 12:383-384
22. Sabry A, Elbasyouni SR (2006) Correlation between levels of TNF-α and IL-6 and hematological involvement in SLE Egyptian Patients with Lupus Nephritis Int J Urol Nephrol 38(4):731-737
23. Cowper SE, Bucala R (2003) Nephrogenic fibrosing dermopathy: Suspect identified, motive unclear. Am J Dermatopathol 25:358
24. Kuwana M, Okazaki Y, Kodama H, Izumi K, Yasuoka H, Ogawa Y, Kawakami Y, Ikeda Y (2003) Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 74:833-845
25. Runge VM (2001) Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12:309-314
26. Peter Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: Suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359-2362
27. Shamsi K, Yucel EK, Chamberlin P (2006) A Summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and phase III clinical trials data. Invest Radiol 41:822-830
28. Thomsen HS, Morcos SK, Dawson P (2006) Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis. Clin Radiol 61:905-906
29. Swan SK, Lambrecht LJ, Townsend R, Davies BE, McCloud S, Parker JR, Bensel K, LaFrance ND (1999) Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 34:443-455
30. Reinton V, Berg KJ, Svaland MG, Andrew E, Normann PJ, Rootwelt K (1994) Pharmacokinetics of gadodiamide injection in patients with moderately impaired renal function. Acta Radiol 1:56-61
31. Schuhmann-Giampieri G, Krestin G (1991) Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 11:975-979
32. Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acta Radiol 5:491-502
33. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y (2006) Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 24:445-451
34. Okada S, Katagirir K, Kumazaki T, Yokoyama H (2001) Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol 42:339-341
35. Jiménez SA, Artlett CM, Sandorfi N et al (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): Study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50(8):2660-2666
36. Sadowski EA, Bennett LK et al (2007) Nephrogenic systemic fibrosis: Risk factors and incidence estimation Radiology 243:148-157
37. Mackay-Wiggan JM, Cohen DJ, Hardy MA et al (2003) Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48(1):55-60
38. Swaminathan S, Ahmed I, McCarthy JT, Albright RC, Pittelkow MR, Caplice NM, Griffin MD, Leung N (2006) Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145:234-235
39. Centers for Disease Control and Prevention (2007) Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 56:137-141
40. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS (2007) Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 17:2359-2362
41. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M (1990) Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 87:5978-5982
42. Ammarguellat F, Llovera M, Kelly PA, Goffin V (2001) Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 284:1031-1038
43. Desai A, Zhao Y, Lankford HA, Warren JS (2006) Nitric oxide suppresses EPO-induced monocyte chemoattractant protein-1 in endothelial cells: implications for atherogenesis in chronic renal disease. Lab Invest 86:369-379
44. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B (2000) Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95:2983-2989
45. George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A (2005) Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 68:299-306
46. Galeano M, Altavilla D, Bitto A, Minutoli L, Calo M, Lo Cascio P, Polito F, Giugliano G, Squadrito G, Mioni C, Giuliani D, Venuti FS, Squadrito F (2006) Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds. Crit Care Med 34:1139-1146
47. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102:1340-1346
48. Haroon ZA, Amin K, Jiang X, Arcasoy MO (2003) A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 163:993-1000
49. Meneghin A, Hogaboam CM (2007) Infectious disease, the innate immune response, and fibrosis. J Clin Invest 117:530-538
50. De Marchi S, Cecchin E, Falleti E, Giacomello R, Stel G, Sepiacci G, Bortolotti N, Zanello F, Gonano F, Bartoli E (1997) Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 8:1147-1156
51. Centers for Disease Control and Prevention (2002) Fibrosing skin condition among patients with renal disease - United States and Europe, 1997-2002. MMWR Morb Mortal Wkly Rep 18; 51(2):25-26
52. High WA, Ayers RA, Chandler J, Zito G, Cowper SE (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 1:21-26
53. Jan F, Segal JM, Dyer J et al (2003) Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 143(5):678-681
54. Streams BN, Liu V, Liegeois N, Moschella SM (2003) Clinical and pathologic features of nephrogenic fibrosing dermopathy: A report of two cases. J Am Acad Dermatol 48(1):42-47
55. Narayanan KM, Nickel AE, Runge VM, Greene JF (2007) J Invest Radiol 42:139-145
56. Ortonne N, Lipsker D, Chantrel F et al (2004) Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: A new pathogenic hypothesis. Br J Dermatol 150(5):1050-1052
57. Edsall LC, English JC, Teague MW, Patterson JW (2004) Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 31(3):247-253
58. Thomsen HS (2007) European Society of Urogenital radiology guidelines on contrast media application. Curr Opin Urol 17(1):70-76
59. Schmook T, Budde K, Ulrich C et al (2005) Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 20(1):220-222
60. Kafi R, Fisher GJ, Quan T et al (2004) UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 140(11):1322-1324
61. Kucher C, Xu X, Pasha T, Elenitsas R (2005) Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol 32(7):484-490
62. Läuchli S, Zortea-Caflisch C, Nestle FO et al (2004) Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 208(3):278-280
63. Scheinfeld N, MD, S. Cowper, MD, emedicine /derm/ topic934
64. Apostolou T (2007) Quality of life in the elderly patients on dialysis Int J Urol Nephrol 39(2):679-689
65. Roberts R, Jeffrey C (2007) Prospective investigation of the incidence of falls, dizziness and syncope in hemodialysis patients Int J Urol Nephrol 39(1):275-279